SavedAdd your journal

Journals / Bağcılar Tıp Bülteni / 2021 / Cilt: 6 - Sayı: 1

CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel

Clopidogrel Kullanan, Koroner Arter Hastalığı Tanısı Mevcut Olan Türk Popülasyonunda CYP2C19*1 ve CYP2C19*2 Gen Polimorfizmi

Aylin KÖSELER
Ramazan SABIRLI
Atakan YILMAZ
İsmail Doğu KILIÇ
Pages
53–60
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We found CYP2C19*1/2 and CYP2C19*2/2 genotype to be higher in the CAD patients than in the control group, highlighting the importance of checking CYP2C19 gene polymorphism prior to the initiation of antiplatelet therapy in CAD patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The CYP2C19*1 has an entirely normal activity allele whose clopidogrel metabolism is normal.
📊
Key Findings & Data:CYP2C19*2 called as non-functional alleles.
💡
Conclusion & Impact:Conclusion: We found CYP2C19*1/2 and CYP2C19*2/2 genotype to be higher in the CAD patients than in the control group, highlighting the importance of checking CYP2C19 gene polymorphism prior to the initiation of antiplatelet therapy in CAD patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The CYP2C19*1 has an entirely normal activity allele whose clopidogrel metabolism is normal. CYP2C19*2 called as non-functional alleles. In this study, we aimed to establish the CYP2C19*1 and CYP2C19*2 genotype frequencies both in Turkish patients with coronary artery disease (CAD), who used clopidogrel, and in healthy Turkish population as well as to present the differences in genotypes and alleles between both groups. Method: One hundred healthy individuals and 200 patients diagnosed with CAD were included in the study. DNA was isolated and CYP2C19gene was amplified through the polymerase chain reaction method in the genomic DNAs obtained, and the polymorphic foci in these regions were specified.Results: CYP2C19*1/1 genotype was identified in 132 patients (66%), CYP2C19*1/2 genotype in 62 patients (31%) and CYP2C19*2/2 genotype in 6 patients (3%) in the CAD group. In the control group, by contrast, 72 patients (72%) were identified with CYP2C19*1/1 genotype, 20 patients with CYP2C19*1/2 genotype and 8 patients with CYP2C19*2/2 genotype. There was a significant difference between the groups in terms of genotypes (p=0.034). Conclusion: We found CYP2C19*1/2 and CYP2C19*2/2 genotype to be higher in the CAD patients than in the control group, highlighting the importance of checking CYP2C19 gene polymorphism prior to the initiation of antiplatelet therapy in CAD patients.

Özet

Amaç: CYP2C19*1, klopidogrel metabolizması normal olan tamamen normal bir aktiviteye sahiptir. CYP2C19*2, işlevsel olmayan aleller olarak adlandırılır. Bu çalışmada, hem klopidogrel kullanan ve koroner arter hastalığı (KAH) olan Türk hastalarda hem de sağlıklı Türk popülasyonunda CYP2C19*1 ve CYP2C19*2 genotip frekanslarını belirlemeyi ve her iki grup arasındaki genotip ve alel farklılıklarını sunmayı amaçladık. Yöntem: Çalışmaya 100 sağlıklı birey ve KAH tanısı almış 200 hasta dahil edildi. DNA izole edilerek ve CYP2C19 geni polimeraz zincirleme reaksiyonu yöntemi ile amplifiye edilerek bu bölgelerdeki polimorfik odaklar belirlendi. Bulgular: KAH grubunda 132 hastada (%66) CYP2C19*1/1 genotipi, 62 hastada (%31) CYP2C19*1/2 genotipi ve 6 hastada (%3) CYP2C19*2/2 genotipi tespit edildi. Kontrol grubunda ise 72 hasta (%72) CYP2C19*1/1 genotipi, 20 hasta CYP2C19*1/2 genotipi ve 8 hasta CYP2C19*2/2 genotipi ile tanımlanmıştır. Genotipler açısından gruplar arasında anlamlı fark vardı (p=0,034). Sonuç: KAH hastalarında CYP2C19*1/2 ve CYP2C19*2/2 genotipinin kontrol grubuna göre daha yüksek olduğunu belirledik. Bu da koroner arter hastalarında antiplatelet tedaviye başlamadan önce CYP2C19 gen polimorfizminin bakılmasının önemli olduğunu vurgulamaktadır.

🔖

Cite This Article

KÖSELER, A., SABIRLI, R., YILMAZ, A., KILIÇ, İ. D. (2022). CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel. Bağcılar Tıp Bülteni, Cilt: 6 - Sayı: 1, 53–60. https://ajindex.com/articles/458954

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. De Morais, SM, Wilkinson, GR, Blaisdell, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46(4):594-598
  2. De Morais SM, Wilkinson GR, Blaisdell, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269(22):15419-15422
  3. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein MC. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56(4):321-341
  4. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6(6):521-526
  5. Masimirembwa C, Bertilsson L, Johansson I, Hasler A, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57(6):656-661
  6. He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol 2002;58(1):15-18
  7. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281(1):604-609
  8. Ding Y, Xu D, Zhang X, Yang H, Geng T, He P, et al. Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population. Int J Clin Exp Pathol 2015;8(10):13201-13208
  9. Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, et al. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenomics Pers Med 2013;6:85-91
  10. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50(2):195-200
  11. Zhong Z, Hou J, Li B, Zhange, Zhang Q, Liu S, Li C, et al. Analys